The agency's Committee for Medicinal Products for Human Use had recommended not granting an authorization as the observed benefits did not counterbalance the risk of serious side events, especially brain swelling and bleeding or microhemorrhages.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/L0aKwnO
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment